infect
novel
coronaviru
caus
death
vaccin
specif
therapeut
antibodi
current
avail
reli
spike
protein
particular
receptor
bind
domain
rbd
bind
human
cell
receptor
angiotensinconvert
enzym
viral
entri
thu
target
rbd
hold
promis
prevent
infect
work
competit
biopan
strategi
phage
display
antibodi
librari
appli
screen
block
antibodi
rbd
highaffin
antibodi
enrich
first
round
use
standard
pan
process
rbdhi
recombin
protein
immobil
bait
next
two
round
immobil
free
rbdhi
protein
mix
enrich
phage
antibodi
antibodi
bind
rbd
epitop
differ
site
captur
immobil
form
sandwich
complex
antibodi
compet
recogn
rbd
similar
epitop
bind
free
rbdhi
supernat
subsequ
separ
ninta
magnet
bead
top
lead
competit
biopan
synthet
antibodi
librari
lib
produc
fulllength
format
prove
competit
block
bind
rbd
protein
potent
inhibit
pseudoviru
infect
hela
cell
valu
nevertheless
top
lead
standard
biopan
lib
bind
rbd
vitro
block
neutral
activ
strategi
effici
isol
block
antibodi
rbd
would
speed
discoveri
neutral
antibodi
authorfund
right
reserv
reus
allow
without
permiss
recent
outbreak
novel
coronaviru
diseas
emerg
public
health
emerg
intern
concern
global
pandem
pathogen
newli
identifi
coronaviru
got
famili
name
spike
protein
viral
particl
highli
glycosyl
protein
stay
compact
trimer
state
recogn
receptor
host
cell
membran
undergo
seri
conform
chang
proteolysi
event
membran
fusion
complet
viral
entri
vaccin
clinic
diagnosi
earli
prevent
medic
protein
signific
target
primari
sequenc
protein
sever
acut
respiratori
syndrom
coronaviru
sarscov
share
ident
similar
indic
high
possibl
structur
homolog
infect
pathway
sarscov
recogn
host
cell
receptor
mediat
viral
entri
host
cell
report
sarscov
protein
trimer
bound
ratio
infect
rbd
sarscov
monom
partial
buri
inact
conform
abl
bind
due
steric
clash
infect
start
one
monom
turn
rbd
expos
enough
space
induc
conform
open
loos
proteolysi
atomiclevel
structur
analysi
suggest
spatial
interact
interfac
rbd
mostli
accord
sarscov
case
besid
cryoem
structur
protein
trimer
publish
recent
show
one
three
rbd
conform
natur
expos
whole
interact
interfac
classic
close
symmetr
trimer
still
exist
might
explain
much
contagi
sarscov
caus
tricki
problem
worldwid
effect
cure
vaccin
current
avail
base
structur
inform
block
rbd
ration
therapeut
approach
develop
competit
biopan
strategi
effici
isol
block
antibodi
phage
display
antibodi
librari
sever
highaffin
antibodi
target
rbd
block
bind
isol
top
lead
exhibit
neutral
activ
pseudotyp
vsv
infect
recombin
protein
purchas
novoprotein
shanghai
china
rbdhi
purchas
sino
biolog
beij
china
rbdmfc
express
use
ablink
biotech
hek
express
system
synthet
human
fab
antibodi
librari
construct
accord
procedur
previous
describ
human
germlin
immunoglobulin
variabl
segment
employ
templat
complementaritydetermin
region
diversifi
design
mutagen
oligonucleotid
oligonucleotid
synthes
use
trimer
phosphoramidit
mix
z
glen
research
contain
codon
amino
acid
follow
molar
ratio
g
p
h
r
f
w
v
l
number
posit
denot
z
qq
z
n
plt
ar
z
n
agdi
fdi
vari
respect
librari
size
estim
antibodi
rbd
screen
first
round
use
standard
biopan
protocol
briefli
rbdhi
coat
maxisorp
plate
overnight
coat
buffer
decant
plate
block
polyvinyl
alcohol
pva
room
temperatur
hour
phage
librari
pfuml
ad
per
well
bind
wash
eight
time
pt
buffer
pb
bound
phage
elut
hcl
per
well
follow
incub
eluent
transfer
microfug
tube
neutral
trishcl
ph
half
neutral
phage
solut
mix
activ
grow
e
coli
neb
f
media
contain
tetracyclin
incub
hour
pfu
helper
phage
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
ad
next
incub
anoth
hour
infect
bacteria
amplifi
medium
contain
carbenicillin
kanamycin
shake
grow
overnight
next
day
phage
harvest
precipit
pegnacl
solut
resuspend
pb
buffer
follow
round
pan
first
round
standard
biopan
competit
biopan
protocol
includ
step
competit
bind
magnet
separ
elut
amplif
appli
isol
epitopespecif
antibodi
briefli
protein
coat
maxisorp
plate
well
wash
block
pva
mixtur
antibodi
librari
pfu
per
well
free
rbdhi
protein
per
well
ad
competit
bind
supernat
transfer
microfug
tube
contain
prewash
ninta
magnet
bead
genscript
incub
shaker
room
temperatur
hour
bead
collect
use
magnet
separ
rack
wash
pt
buffer
time
bound
phage
elut
hcl
per
tube
incub
bead
collect
use
magnet
separ
rack
supernat
transfer
tube
neutral
half
neutral
phage
solut
mix
activ
grow
neb
alpha
f
cell
amplifi
standard
biopan
protocol
bacteri
cultur
infect
helper
phage
taken
dilut
grown
lb
plate
contain
carbenicillin
overnight
singl
clone
pick
next
day
phage
elisa
assay
schemat
present
competit
biopan
strategi
specif
binder
target
protein
ad
bind
step
select
block
antibodi
work
immobil
captur
rbdhi
antibodi
bind
rbd
differ
epitop
form
complex
like
sandwich
howev
antibodi
recogn
similar
epitop
within
rbd
could
block
interact
antibodi
would
bind
free
rbdhi
supernat
subsequ
separ
ninta
magnet
bead
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
phage
elisa
singl
clone
inocul
medium
contain
carbenicillin
kanamycin
pfuml
helper
phage
plate
incub
overnight
plate
centrifug
supernat
appli
phage
elisa
maxisorp
plate
coat
overnight
rbdmfc
per
well
block
pva
plate
incub
bacteri
supernat
contain
phage
hour
room
temperatur
six
time
wash
pt
bound
phage
detect
use
hrpconjug
antibodi
sino
biolog
tetramethyl
benzidin
tmb
substrat
absorpt
measur
vh
vl
posit
phage
subclon
respect
pfusessclighk
invitrogen
antibodi
transient
express
hek
cell
life
technolog
use
transfect
reagent
accord
manufactur
instruct
transfect
cell
grown
serumfre
medium
addit
day
supernat
collect
purifi
mabselect
protein
column
ge
healthcar
elut
igg
dialyz
pb
store
recombin
human
per
well
coat
maxisorp
plate
follow
preincub
mixtur
antirbd
antibodi
titrat
constant
amount
rbdmfc
rbd
bind
detect
use
hrp
conjug
antimous
fc
antibodi
neutral
effect
antibodi
pseudoviru
perform
genscript
inc
nanj
china
research
servic
contract
briefli
human
hela
monoclon
cell
seed
well
plate
pseudoviru
antibodi
incub
ambient
temperatur
hour
mixtur
transfer
well
incub
cell
hour
cultur
medium
freshli
replac
cell
incub
anoth
hour
cultur
medium
remov
cell
rins
pb
lysi
buffer
ad
incub
ambient
temperatur
minut
supernat
transfer
steril
unclear
plate
bioglo
luciferas
substrat
ad
luminesc
signal
measur
envis
dose
respons
curv
plot
rel
luminesc
unit
antibodi
concentr
assay
result
process
microsoft
offic
excel
graphpad
prism
highaffin
antibodi
identifi
phage
elisa
round
competit
biopan
clone
randomli
select
properti
bind
rbd
measur
use
phage
elisa
posit
bind
defin
read
two
time
higher
neg
control
pva
alon
clone
show
posit
signal
dna
sequenc
clone
summar
group
uniqu
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
antibodi
identif
posit
clone
immobil
antigen
competit
manner
taken
read
measur
data
group
fluctuat
within
highestrank
one
name
work
lead
highest
read
isol
competit
biopan
top
lead
isol
standard
biopan
round
express
fulllength
antibodi
use
express
system
bind
block
abil
rbd
compar
high
affin
rbd
respect
block
bind
rbd
posit
control
recombin
total
inhibit
infect
hela
monoclon
cell
pseudoviru
antibodi
show
signific
neutral
activ
pseudoviru
valu
howev
antibodi
neutral
effect
pseudoviru
signific
differ
highest
concentr
antibodi
group
blank
group
without
antibodi
addit
two
rbdspecif
antibodi
select
differ
strategi
show
differ
neutral
activ
antibodi
compet
could
neutral
pseudoviru
could
nt
interact
initi
viral
infect
sarscov
rbd
share
high
sequenc
ident
structur
homolog
wellestablish
sarscov
antibodi
firstli
assum
shortcut
therapeut
candid
howev
real
scenario
much
problemat
sever
independ
peerreview
studi
well
preprint
one
prove
structur
known
sarscov
specif
antibodi
includ
crossreact
antibodi
compet
bind
sarscov
rbd
epitop
limit
overlap
full
interfac
could
reason
lack
crossreact
special
case
conserv
key
residu
epitop
sarscov
crossreact
remark
one
site
loss
nglycan
result
magnitud
reduct
bind
affin
rbd
human
life
rbdspecif
monoclon
antibodi
deriv
recov
individu
indic
similar
pattern
crossreact
either
sarcov
merscov
gener
structur
function
analysi
suggest
target
rbd
could
direct
promis
therapeut
strategi
focus
previou
sarscov
antibodi
ideal
effici
rbdspecif
monoclon
antibodi
report
human
antibodi
librari
april
th
meantim
spread
unexpectedli
fast
around
world
new
studi
shift
basic
reproduct
number
rapid
effect
method
obtain
neutral
antibodi
much
requir
antibodi
librari
deriv
natur
immun
system
capac
limit
synthet
librari
higher
divers
opportun
isol
binder
especi
novel
infecti
antigen
compar
antibodi
librari
divers
synthet
librari
addit
artifici
random
cdr
reach
divers
high
recombin
rbd
protein
readi
took
week
isol
produc
verifi
antibodi
studi
use
standard
biopan
method
enrich
rbdspecif
phage
synthet
lib
antibodi
librari
data
shown
unfortun
lead
standard
biopan
lib
could
nt
block
interact
fig
although
bind
rbd
fig
clinic
potenti
applic
antibodi
often
depend
bind
epitop
target
protein
highaffin
antibodi
target
protein
screen
phage
display
antibodi
librari
use
standard
biopan
process
bind
epitop
identifi
extra
step
epitop
map
competit
elisa
therefor
develop
new
competit
biopan
strategi
effici
isol
isotypespecif
antibodi
librari
expect
lead
success
bind
rbd
compet
solut
pseudoviru
bind
affin
quit
high
differ
measur
method
conclus
strateg
discoveri
human
monoclon
antibodi
rbd
may
fill
blank
antibodyrel
pharmaceut
develop
shed
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
light
new
treatment
need
global
health
concern
